Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

INTRODUCTION: Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric symptoms have not been systemically quantified using structured scales. This...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS Res Ther
Main Authors: Chan, Phillip, Goh, Orlanda, Kroon, Eugène, Colby, Donn, Sacdalan, Carlo, Pinyakorn, Suteeraporn, Prueksakaew, Peeriya, Reiss, Peter, Ananworanich, Jintanat, Valcour, Victor, Spudich, Serena, Paul, Robert
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6945418/
https://ncbi.nlm.nih.gov/pubmed/31907064
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12981-019-0257-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados